Mr Perfusion-derived hemodynamic Parametric response Mapping of Bevacizumab efficacy in recurrent glioblastoma

Radiology

Volumn 279, Issue 2, 2016, Pages 542-552

  Kickingereder, Philipp ^a   Radbruch, Alexander ^a,b   Burth, Sina ^a   Wick, Antje ^a   Heiland, Sabine ^a   Schlemmer, Heinz Peter ^b   Wick, Wolfgang ^a,b   Bendszus, Martin ^a   Bonekamp, David ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; CONTRAST MEDIUM; GADOTERATE MEGLUMINE; MEGLUMINE; MONOCLONAL ANTIBODY; ORGANOMETALLIC COMPOUND;

ARTICLE; BRAIN BLOOD FLOW; BRAIN MAPPING; BRAIN PERFUSION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; GLIOBLASTOMA; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TISSUE OXYGENATION; TUMOR BLOOD FLOW; BRAIN CIRCULATION; BRAIN NEOPLASMS; COMPUTER ASSISTED DIAGNOSIS; FEMALE; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BEVACIZUMAB; BRAIN NEOPLASMS; CEREBROVASCULAR CIRCULATION; CONTRAST MEDIA; FEMALE; GLIOBLASTOMA; HEMODYNAMICS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MEGLUMINE; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; ORGANOMETALLIC COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84965111409     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2015151172     Document Type: Article

References (26)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (Berl) 2007;114(2):97-109.
2. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neurooncol 2014;16(Suppl 4):iv1-iv63.
3. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28(11):1963-1972.
4. Leu K, Pope WB, Cloughesy TF, et al. Imaging biomarkers for antiangiogenic therapy in malignant gliomas. CNS Oncol 2013;2(1): 33-47.
5. Nowosielski M, Wiestler B, Goebel G, et al. Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology 2014;82(19): 1684-1692.
6. Pope WB. Predictive imaging marker of bevacizumab efficacy: perfusion MRI. Neuro-oncol 2015;17(8):1046-1047.
7. Ostergaard L, Tietze A, Nielsen T, et al. The relationship between tumor blood flow, angiogenesis, tumor hypoxia, and aerobic glycolysis. Cancer Res 2013;73(18): 5618-5624.
8. Verhoeff JJ, Lavini C, van Linde ME, et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol 2010;21(8):1723-1727.
9. Zhang W, Kreisl T, Solomon J, et al. Acute effects of bevacizumab on glioblastoma vascularity assessed with DCE-MRI and relation to patient survival [abstr]. In: Proceedings of the Seventeenth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2009; 282.
10. Schmainda KM, Prah M, Connelly J, et al. Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro-oncol 2014;16(6):880-888.
11. Kickingereder P, Wiestler B, Burth S, et al. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Neuro-oncol 2015;17(8):1139-1147.
12. Kickingereder P, Wiestler B, Graf M, et al. Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab. J Neurooncol 2015;121(2): 373-380.
13. Schmainda KM, Zhang Z, Prah M, et al. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Neurooncol 2015;17(8):1148-1156.
14. Galbán CJ, Chenevert TL, Meyer CR, et al. The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 2009;15(5):572-576.
15. Kickingereder P, Wiestler B, Sahm F, et al. Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging. Radiology 2014;272(3):843-850.
16. Mouridsen K, Christensen S, Gyldensted L, Ostergaard L. Automatic selection of arterial input function using cluster analysis. Magn Reson Med 2006;55(3):524-531.
17. Wu O, Østergaard L, Weisskoff RM, Benner T, Rosen BR, Sorensen AG. Tracer arrival timing-insensitive technique for estimating flow in MR perfusion-weighted imaging using singular value decomposition with a block-circulant deconvolution matrix. Magn Reson Med 2003;50(1):164-174.
18. Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages: part I-mathematical approach and statistical analysis. Magn Reson Med 1996;36(5):715-725.
19. Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002; 17(2):825-841.
20. Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal 2001;5(2): 143-156.
21. Yushkevich PA, Piven J, Hazlett HC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage 2006;31(3):1116-1128.
22. Grabner G, Janke AL, Budge MM, Smith D, Pruessner J, Collins DL. Symmetric atlasing and model based segmentation: An application to the hippocampus in older adults. Med Image Comput Comput Assist Interv 2006 ;9(Pt 2):58-66.
23. Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM. FSL. Neuroimage 2012;62(2):782-790.
24. Ellingson BM, Zaw T, Cloughesy TF, et al. Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)-MRI estimates of cerebral blood volume (CBV) in human gliomas. J Magn Reson Imaging 2012;35(6):1472-1477.
25. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8(8):592-603.
26. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6(6):553-563.